1. In Vivo
  2. >>Innovation

Atlas Genetics Ready To Play Its Part In The POC Workflow Revolution

 
• By Ashley Yeo

Do it once, do it right and do it quick: when it comes to diagnostic testing, that suits patients and payer systems that are pursuing budget-sensitive, quality-driven health care solutions. It could also be the shorthand mission statement of POC diagnostics developer Atlas Genetics, which is developing a new IVD platform technology for infectious disease tests.

IV1611_Atlas_1200x675

UK company Atlas Genetics Ltd. was founded in 2005 as a spin-out from Osmetech PLC and the University of Bath to exploit the point of care (POC) market for infectious diseases. When John Clarkson, PhD, joined US-based and UK-listed Osmetech as incoming CEO of the unit that became Atlas Genetics Ltd. he recognized that the company was under-utilizing some of its IP assets and saw both the opportunity – and the challenges – of developing its infectious disease diagnostic chemistry.

Clarkson had to strike the right balance of investment: it had to remain modest until the company had developed a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Innovation

Johnson & Johnson MedTech: How To Scale Digital Solutions

 
• By Natasha Barrow

J&J's EMEA head of digital solutions, Julia Fishman, talks about the hurdles in scaling digital innovation and what’s up next on J&J’s innovation road map. Robot-assisted surgery pioneer Ivo Broeders gives his perspective on the difficulties in clinical adoption.

How Ethris Cracked mRNA’s “Do Not Shake” Problem To Unlock Respiratory Therapeutics

 
• By Jo Shorthouse

A German biotech has solved a fundamental physics problem that has limited mRNA therapeutics to injectable vaccines. Its breakthrough stabilizer technology allows mRNA particles to survive the mechanical stress of inhalation delivery, opening the door to treating chronic respiratory diseases.

Finding The Fire: AltruBio’s Novel Approach To Autoimmune Disease

 
• By David Wild

CEO Judy Chou brings big pharma experience to tackle chronic inflammation with the company's first-in-class PSGL-1 targeting therapy.

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By David Wild

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

More from In Vivo

Pharma’s Dance With Trump Risks Distracting From Longer-Term Threats

 
• By Melanie Senior

Industry is trying to side-step President Trump’s tariff- and price-curbing policy proposals. It may do better facing up to enduring R&D productivity and drug affordability challenges.

Tackling Fraud In The UK: Pharma, Are You Ready?

 
• By Trevor Francis

UK pharma faces a critical turning point as the Economic Crime and Corporate Transparency Act introduces the "Failure to Prevent Fraud" offense in September 2025, requiring companies to transform their approach to fraud prevention or face severe consequences.

Rising Leaders 2025: Kura Oncology’s Mollie Leoni On Setting Precedent, Not Following It

 
• By Jo Shorthouse

Kura Oncology's new chief medical officer discusses her path to leadership, the company's advancing AML pipeline, and her methodical approach to developing treatments for underserved oncology indications.